Michael Bison is a partner in Goodwin’s nationally recognized Life Sciences and Technology Companies Practice Groups. He has over 15 years of experience representing privately held and publicly traded emerging growth companies with a strong emphasis on companies across the spectrum of the life sciences industry, including biotechnology, medical devices, diagnostics and healthcare information technology. Mr. Bison also regularly represents leading venture capital firms focused on the life sciences industry in connection with their portfolio company investments, M&A and secondary stock sale transactions, as well as underwriters focused on the life sciences industry in connection with capital market and M&A transactions.

Mr. Bison often serves as outside general counsel to his clients, closely advising management teams and boards of directors on a wide variety of matters throughout the company’s life cycle, including company formation and founder issues, venture capital and growth equity financings, public offerings, mergers and acquisitions, strategic collaborations, commercial transactions, corporate governance and general corporate matters.

Mr. Bison serves on the board of directors of MassMEDIC, an organization of medical device manufacturers, suppliers and associated non-profit groups in Massachusetts and the surrounding region. He has been selected for inclusion in The Legal 500 and recognized as a Massachusetts Super Lawyer “Rising Star” by Law & Politics and Boston magazines. He is regularly recognized by his clients for his extensive industry knowledge and for providing practical, result-oriented legal advice.

Experience

Erfahrung

工作经历

Representative Matters

Repräsentative Angelegenheiten

代表事项

IPOs and Follow-On Transactions
  • Argenx in its $114.7 million initial public offering
  • Chiasma in its $101.8 million initial public offering
  • Galapagos NV in its $275 million initial public offering and initial U.S. listing and $371.1 million follow-on offering
  • DBV Technologies S.A. in its $133.1 million global offering and initial U.S. listing
  • Sage Therapeutics in its $103.5 million initial public offering and $138 million follow-on offering
  • bluebird bio in its $116.1 million initial public offering and $117.3 million, $500 million, $400 million follow-on offerings
  • Amarin Corporation in its $121.2 million, $87.5 million and $69.1 million follow-on offerings
  • Amarin Corporation in its $150 million 144A note offering and $118.7 million privately negotiated note exchange
  • J.P. Morgan and Barclays Capital in the $184 million initial public offering of Intrexon Corporation
  • Leerink Partners in a $57.5 million follow-on offering for Ovascience
  • BofA Merrill Lynch and Leerink Partners in the $60 million initial public offering of Roka Bioscience
  • Aegerion Pharmaceuticals in its $54.6 million initial public offering
  • LeMaitre Vascular in its $38.5 million initial public offering
  • athenahealth in its $90 million initial public offering
Private Company Financing Transactions
  • Exosome Diagnostics in its $30 million Series C financing
  • Docent Health in its $17 million Series A financing
  • GliaCure in its $6 million Series B financing
  • Mitralign in its $40 million Series E financing
  • Exosome Diagnostics in its $27 million Series B financing
  • HealthWyse in multiple rounds of private financing (undisclosed)
  • meQuilibrium in multiple rounds of private financing (undisclosed)
  • bluebird bio in its $35 million Series C and $60 million Series D financing transactions
  • FRX Polymers in its $26.7 Series B, $20 million Series C and $22 million Series D financing transactions
  • Zeo in its $8.3 million Series C and $12.3 million Series D financing transactions
M&A Transactions
  • HealthWyse in its sale to Casamba / ABRY Partners
  • bluebird bio (NASDAQ: BLUE) in its acquisition of Precision Genome Engineering
  • VitalMed in its sale to PPC Industries
  • TrialNetworks in its sale to DrugDev
  • Outcome Sciences in its sale to Quintiles Transnational (NASDAQ: Q)
  • Mpathy Medical in its sale to Coloplast (COLOB.CO)
  • Progentix Orthobiology in its sale to NuVasive (NASDAQ: NUVA)
  • Ascension Ventures and others in the acquisition of MedVentive by McKesson Corporation (NYSE: MCK)
  • Ascension Ventures in the acquisition of BodyMedia by Jawbone
  • Forbion Capital Partners and others in the acquisition of BioVex by Amgen (NASDAQ: AMGN)
Venture Capital Transactions
  • Frazier Healthcare Partners, New Leaf Ventures, Soffinova Ventures and Canaan Partners in connection with a venture investment in Iterum Therapeutics
  • Bessemer Venture Partners and others in multiple rounds of venture investment in Acceleron Pharma, Fractyl Laboratories, Ovascience, Verastem, Proteon Therapeutics, Sirtris Pharmaceuticals and others
  • Third Rock Ventures and others in multiple round of venture investment in Allena Pharmaceuticals and Alcresta
  • Abingworth Life Sciences and others in connection with venture investments in Chiasma and Avedro
  • Ascension Ventures and others in multiple rounds of venture investment in BodyMedia, Inc., Ocular Therapeutix, Vascular Pathways, Cheetah Medical and others
  • Lightstone Ventures and others in connection with a venture investment in Catabasis
  • Forbion Capital Partners and others in multiple rounds of venture investment in Circulite, Mitralign, Pathway Medical, Promedior and others
  • Other leading VC firms, including Flagship Ventures, General Catalyst Partners, Advanced Technology Ventures and MVM Life Sciences, in connection with their portfolio investments and related matters
Professional Activities

Mr. Bison serves on the board of directors of MassMEDIC and is a member, through the firm, of the Biotechnology Industry Organization (BIO) and Massachusetts Biotechnology Council (MBC). He is also a member of the American and Boston Bar Associations.

Mr. Bison serves on the board of directors of The Achievement Network (ANet), a non-profit organization committed to helping students achieve academic excellence through the delivery of data-driven strategies to identify and close gaps in student learning.

Professional Experience

Prior to joining Goodwin, Mr. Bison was a member of the Business Practice Group at Testa, Hurwitz & Thibeault, LLP in Boston. Prior to beginning his legal career, he was a business and information systems consultant at Andersen Consulting, LLP (now Accenture Ltd.).

Recognition

Mr. Bison has been selected for inclusion in The Legal 500 and was recognized as a Massachusetts Super Lawyer “Rising Star” by Law & Politics and Boston magazines.

In The News

In den Nachrichten

在新闻中

Credentials

Anmeldeinformationen

专业资格

Education

J.D., 1998
Northeastern University School of Law
B.A., 1993
College of the Holy Cross

(cum laude)

Admissions

Bar

Massachusetts
Get In Touch
In Kontakt kommen
Get In Touch
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
Suche Andere Rechtsanwälte
搜寻其他律师